Global Dilated Cardiomyopathy Therapeutics Market Is Expected Reach US$411.6 mn by 2027

 

Dilated cardiomyopathy (DCM) is a leading cause of heart failure and a leading indication for heart transplantation in both children and adults worldwide. This condition is distinguished by ventricular chamber enlargement, thinning of the heart walls, and an inability to adequately pump blood throughout the body. Dilated cardiomyopathy can occur at any age, but it is more common in people aged 20 to 60. Genetic inheritance is found to affect approximately 30% to 40% of all DCM patients. Single gene mutations in myocyte structural proteins such as dystrophin, metavinculin, lamin, and mitochondrial DNA are also common causes of DCM. Other factors such as diabetes, thyroid disorder, alcoholism, viral infections of the heart, and heart valve abnormalities can also lead to dilated cardiomyopathy. Moreover, according to the Pediatric Cardiomyopathy Registry, DCM occurs at a rate of 6 per million children. It is commonly diagnosed in younger children with an average age of diagnosis at 2 years. 

The global market for Dilated Cardiomyopathy Therapeutics, which was estimated to be worth US$304.5 million in 2020, is expected to grow to US$411.6 million by 2027, at a CAGR of 4.4 percent between 2020 and 2027.

The global dilated cardiomyopathy therapeutics market is examined from two angles: drug class and geography. There is currently no FDA-approved drug for the treatment of dilated cardiomyopathy. Because of this, the drug classes used to treat dilated cardiomyopathy are essentially the same as those used to treat congestive heart failure. Aldosterone antagonists, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and beta-blockers are some of the most commonly prescribed drug classes in dilated

cardiomyopathy treatment. Angiotensin II receptor blockers had the highest revenue share in 2013, followed by beta-blockers.This is due to the high demand for blockbuster drugs in the treatment of dilated cardiomyopathy, particularly in developed regions such as North America and Europe. Aldosterone antagonists experienced rapid growth as a result of the discovered positive impact of aldosterone antagonists when combined with either ARBs or ACE inhibitors in slowing the progression of Duchenne muscular dystrophy (DM).

As DCM is one of the leading causes of heart failure, rising incidences of congestive heart failure around the world are a significant growth driver for the dilated cardiomyopathy therapeutics market. Each year, dilated cardiomyopathy accounts for approximately 30 to 40% of all congestive heart failure cases worldwide. Because of the alarming rise in congestive heart failure cases, several companies have begun clinical trial studies to develop therapeutics for dilated cardiomyopathy. Array BioPharma, for example, is conducting a phase II study for its drug candidate ARRY-371797 for DCM treatment in 2015.

Geographically, the market for dilated cardiomyopathy therapeutics is examined for four regions: North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest market share in terms of revenue in 2013, owing to rising incidences of congestive heart failure and high acceptance of branded drugs. DCM affects approximately five to eight people out of every 100,000 people in the United States. Heart failure affects more than 1% of the Canadian population and accounts for approximately 9% of all deaths.

Because of rising economic standards, rising disposable income, and high demand for generic drugs, the Asia Pacific, and the Rest of the World markets are the fastest growing. Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd. and Vericel Corporation are key players in the global DCM market.